Editorial Diabetes 68 EUROPEAN ENDOCRINOLOGY reported a monotherapy failure of 15% with rosiglitazone, 21% with metformin and 34% with glyburide, at 5 years of therapy. 12 In recent years, however, our approach to the management of T2D has changed.
Earlier use of combination therapy is indicated, using drugs with a complementary mode of action. 13 This evolution in therapy calls for a reassessment of the definition and scope of disease progression, as well as drug durability. This need is made more important by the fact that T2D now occurs in younger adults, who have a longer life expectancy to live with diabetes. 14 
The characteristics of diabetes and methods for measuring its progression
The natural history of T2D is marked by a gradual decline in betacell secretory function; insulin sensitivity, on the other hand, remains constant, and shows no such decline. Disease progression, therefore, can be defined in terms of degree and rate of beta-cell secretory defect, or beta-cell failure. 15 Both anatomical (beta-cell apoptosis) and functional (insulin secretory defect) markers have been used by experts to measure the rate of beta-cell failure. However, a combined anatomic-functional view of beta-cell health, appears the best approach. The three-stage model which lists beta-cell sufficiency, partial/reversible insufficiency, and complete/irreversible insufficiency, also appears a rational way of describing disease progression in T2D. 16 Objective markers are needed, however, and fasting and stimulated serum C-peptide are useful markers for functioning of beta cells. This has minimal relevance in clinical practice, and is used primarily in research settings. Such a definition of disease progression has been used in trials in type 1 diabetes prevention. 17 For T2D, the coefficient of failure, a simple tool developed by Wallace and Mathews, can be used to quantify disease progression in terms of beta-cell function, with various drug therapies. 18 T2D is also characterised by the inevitable decrease in effectiveness of prescribed drugs, and a gradual increase in the intensity of glucoselowering therapy requirements. 11, 12 The necessity to intensify therapy by increasing doses of drugs, increasing frequency of dosage, or adding new drugs, can be taken as a marker of disease progression. While the number of oral drugs prescribed may be a discontinuous variable, insulin dose requirement is a continuous variable which lends itself to this indication. Disease progression in clinical trials in insulin can be assessed by the number of injections required, as well as by the total daily dose requirement. 19 A simple way of assessing disease progression over time is to measure change in HbA1c. 10 A clinically significant change in HbA1c (recommended as an increase by ≥0.5%) using a particular therapy, suggests that beta-cell function has declined over time; this implies progression of disease, in spite of the prescribed therapy. 20 Current discourse highlights the need for multifaceted, comprehensive management of diabetes, as opposed to a purely glucocentric one.
This approach may extend to the definition of disease progression as well. Vascular complications tend to increase with advancing duration of T2D. Improvement in HbA1c, however, can reduce the risk of both macrovascular and microvascular complications. The progression of diabetes may be tracked by the surrogate marker of cardiovascular events. 21 Occurrence of one or more cardiovascular events will imply worsening of T2D. Non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for heart failure are the commonly accepted objective endpoints of cardiovascular progression.
In addition to cardiovascular outcomes, renal health is an integral part of T2D health. Renal outcomes have been the subject of exploratory analyses in earlier cardiovascular outcomes trials, but are now being prespecified as secondary outcomes. 22 New onset, or worsening of retinopathy, therefore, is an attractive candidate for defining disease progression in T2D. 
Comprehensive definition

Progression, outcomes and durability
The last decade, we have witnessed more focus on clinical outcomes in T2D. This is evident from the heightened interest in cardiovascular outcome trials. 21 While such trials are necessary, there is debate regarding their cost-effectiveness and relevance. The concept of disease progression differs from that of outcomes. While progression is dynamic, and is seen as a journey to an end, outcomes suggest a fatalistic approach to a fatal ending. Trials on disease progression study participants, while outcome trials, which are event-driven, tend to study events. Ideally, disease progression should be prevented before it reaches an irreversible stage. Outcome trials, on the other hand, enrol participants who are at high risk, in whom it is assumed that cardiovascular events are inevitable.
The concept of prevention of disease progression, therefore, is a healthoriented one, which appeals more than the pathogenetic outcomeoriented approach. 26 Disease progression is an overarching term which includes the concept of glucose lowering drug(s) durability. Pharmacological research treats durability of a drug as its capacity to maintain HbA1c control over an extended period of time. 27 A more comprehensive definition, however, is in order. We suggest that the durability of a drug, or a drug combination, be defined as its ability to postpone or delay progression of disease, in a safe and well-tolerated manner. Thus, all drugs which are able to postpone loss of glycaemic control, the need for intensification of therapy, and/or onset or worsening of complications, may be termed durable. For such an effect to take place and for a drug to be labelled as durable, we suggest 12 months' use as a minimum time frame. This choice can be explained by the fact that efficacy data relating to most anti-diabetic molecules is 12 months, and changes in therapeutic choice are suggested at 3-month intervals. 28
Summary
The definition proposed for disease progression has been drafted with T2D in mind, and does not extend to prediabetes. Most cases of prediabetes remain undiagnosed, and are evident only when they cross the threshold of T2D. Nevertheless, it is important to assess disease progression in this cohort as well, and this issue should be explored further. One of the main limitations of the proposed definition is that complications of T2D are multifactorial, and to attribute the same to failure of the anti-diabetic medication may be unwarranted. While we have included this in our definition to highlight the importance of thinking beyond HbA1c, we understand that this may not be relevant in all clinical situations.
Disease progression is not just a definition, but a framework for optimal strategy and clinically relevant goals. Delaying disease progression is not only a desired target, but a necessary strategy as well. To achieve this target, one must preferentially use glucose-lowering drugs which are proven to retard disease progression as well as the onset of complications in T2D.
